Page 113 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer
P. 113
Table 11. Monitoring parameters in cohorts that did not report information on triggers for intervention in chronological order of starting
enrollment year
Center, Monitoring schedule PSA Gleason # biopsy cores Imaging Behavioral Additional Triggers for
Country score /% cores indication laboratory interventions
[Pubmed ID] tests
Enrollment
years
Kagawa NR PSA DT based on – – – – – NR
st
Medical 1 PSA >1 mo after
Univ., biopsy. ≥3 values
Japan 153 at intervals ≥1 mo
[10765093] apart for >6 mo.
1990-1998
Kitasato “a DRE,” generally seen – – – Annual – – NR
Univ. every 3-6 mo “as clinical bone
Hospital, circumstances dictated.” scan
Japan 154
[11851612]
1991-2000
Univ. of PSA at 3 mo; then every Biochemical – – – – Hematocrit NR
North 6 mo progression: PSA and
Carolina, level increase in 3 creatinine
US 155 consecutive every 6 mo
measurements and
1991-1996 the total increase
was > 5 ng/mL
Princess For the most part, PSA √ – Repeat – – – NR
Margaret every 3mo for 2 yr and biopsies
hospital, every 6 mo in stable consisted of 10 Note: Pathologic
Canada 156 patients; DRE every 6 cores before progression was
[21211899] mo; a confirmatory 2001 and 15-16 devalued, defined as
biopsy within 12 mo and cores after increased grade,
1995-2010 then every 2–3 yr until 2001. increased number of
the patient reached 80 yr cores to more than 3
of age or refused >3 cores or any or any core
a
treatment core involvement >50%.
involvement
>50%
61